21 results about "Opioid" patented technology

Provided is a method for treating a condition selected from the group consisting of pain, sleep disorder, cancer, Alzheimer's disease, neurodegenerative diseases, ulcer, hypertension, opioid- related adverse effects, inflammation, asthma, glaucoma, neurodevelopment diseases and combinations thereof in a subject in need thereof, the method comprising administering to the subject: a) a first active pharmaceutical ingredient (API) comprising at least one cannabinoid other than CBD and THC; and b) a second API, which is different from the first API.

The invention relates to opioid compounds and uses thereof. The present invention relates to opioid derivatives of Formula I: # imgabs0 # or a pharmaceutically acceptable salt or solvate thereof, wherein R1, R3, R4 and Z are as defined herein in the disclosure. The invention also relates to the use of such compounds for the treatment or prevention of e.g. Pain.

The invention relates to a dosing regimen for sedation with the fast-acting benzodiazepine CNS 7056 in combination with an opioid, in particular fentanyl, whereas CNS 7056 is given in a dose of 2 to 20 mg, preferably between 4 and 9 mg and most preferably between 5 and 8 mg.

The invention provides a method for preparing an opioid reduzate intermediate and application of the opioid reduzate intermediate. The method comprises the following steps: carrying out first reduction reaction on hydrazine hydrate and hydrogen peroxide; the product in the step (1) and a compound shown in a formula I are subjected to a second reduction reaction, a compound shown in a formula II is obtained, and the first reduction reaction and the second reduction reaction are carried out in a continuous flow reactor; r1 is selected from carbonyl and-C-OR5, R5 is selected from hydrogen, C1-20 alkyl, hetero-alkyl and carbonyl, R2 is selected from hydrogen, C1-20 alkyl, hetero-alkyl and carbonyl, R3 is selected from hydrogen, C1-20 alkyl, aryl, hetero-aryl, cycloalkyl, hetero-alkyl, aryl alkyl or hetero-aryl alkyl, and R4 is selected from hydrogen and hydroxyl. According to the method, hydrogen peroxide and hydrazine hydrate in a specific proportion are mixed in a continuous flow reactor, diazene is obtained in situ, diazene reduction replaces hydrogenation reduction reaction, operation is safe and stable, the product yield is high, impurities are few, cost is low, and the method is suitable for industrial large-scale production.

The invention can provide compounds, analogs of blebbistatin, effective and selective inhibitors of nonmuscle myosin II relative to cardiac myosin II. Compounds can be used in the method of treating a disease, disorder, or medical condition in a patient, comprising modulating myosin II ATPase, such as treatment of substance abuse relapse disorder, or of renal disease, cancer and metastasis, benign prostate hyperplasia, hemostasis or thrombosis, nerve injury including retinal damage, lung fibrosis, liver fibrosis, arthrofibrosis, wound healing, spinal cord injury, periodontitis, glaucoma and immune-related diseases including multiple sclerosis; or wherein the disease, disorder, or medical condition comprises addiction including abuse of or addiction to anything classified as a Substance-Related or Addictive Disorder in the Diagnostic and Statistical Manual of Mental Disorders (DSM), such as, but not limited to, cocaine, opioids, amphetamines, ethanol, cannabis / marijuana, nicotine, and activities including gambling.Compounds are of general formula with substituents as defined herein.

The present invention proposes an infusion pump, comprising a housing, a plurality of medicine boxes, a plurality of driving mechanisms and a pump body. The driving mechanisms are arranged in a one-to-one correspondence with the medicine boxes. The driving mechanisms can drive the medicine boxes to move along the accommodating cavity to drive the infusion tube of the medicine box to extend or retract from the opening. The pump body is arranged corresponding to the opening, and the pump body is used to squeeze the infusion tube extending from the opening to output the liquid medicine in the medicine bag. The infusion pump proposed by the present invention is provided with a plurality of medicine boxes, which can simultaneously pre-load and infuse opioids, non-steroidal, sedatives and physiological saline. Each medicine box is equipped with a driving mechanism, which can drive the medicine box to move linearly so that the infusion tube is docked with the pump body. When it is necessary to infuse the liquid medicine in the corresponding medicine box, the driving mechanism can be controlled to drive the medicine box to dock with the pump body, and the pump body can be started to output the required liquid medicine. The present invention realizes the simultaneous infusion of multiple drugs by the medicine injection pump through a simple and ingenious structure, with low cost and good reliability.

Disclosed herein are pharmaceutical compositions having a mixture of at least one active agent and an ion exchange resin, such that the composition releases about 75% or more of the at least one active agent within about 1 hour as measured by in-vitro dissolution in a USP Apparatus 2 (paddle) at about 50 rpm in about 900 ml 0.1N HCl at about 37° C. and related methods. Also disclosed herein are pharmaceutical compositions having a mixture of a drug susceptible to abuse, a non-opioid analgesic and an ion exchange resin, the composition further including at least one gelling agent and related methods.

The application discloses a kind of imide compounds for the photoactivation fluorescent detection method of opioid, comprising the following steps: S1, 1-100 equivalent imide compound, 10-10000 equivalent opioid and 0-100000 equivalent solvent are mixed, and mixture is prepared;S2, using 200nm-500nm light source or natural light is irradiated 5s-5000s to the mixture in S1 at room temperature, fluorescence phenomenon can be detected.This application will amide derivative (solid or liquid), opioid (solid or liquid) and solvent are mixed, under the irradiation of specific wavelength and power light source, imide molecule and the specific structure between drug molecule form similar to exciplex photo-irradiation product, the product will produce structure-dependent fluorescence, to carry out the specific recognition of drug molecule.The method is simple in operation, and sensitivity is high, specificity is strong, so opioid can be efficiently and rapidly qualitatively detected.

The present application belongs to the technical field of drug detection method, and particularly relates to a method for detecting drugs in atmospheric environment samples, comprising the following steps: using the adsorption material of a gas sampling instrument to adsorb the drugs in the gas; after the material adsorbs the drugs, using ultrasonic extraction in an organic solvent or a high-temperature heating method to resolve the drugs; and using high-sensitivity mass spectrometry, molecular immunocolloidal gold or fluorescence method to detect the resolved drugs. The detection method can qualitatively and quantitatively detect the drugs in the atmosphere, and is also suitable for detecting the drugs in the exhaled gas of drug users, and contains new psychoactive drugs such as amphetamines, opioids and synthetic cannabis.

The present disclosure relates to compositions and methods for the promotion and maintenance of oral health. Specifically, the present disclosure relates to pain management, promoting healing, reducing post-surgical edemas, reducing the need for the opioids in post-surgical pain management, treating various inflammatory conditions in the oral cavity, general maintenance of a healthy oral cavity, and general dental care. The present disclosure presents compositions and methods for promoting and maintaining oral health, including decreasing pain, inflammation, swelling, and bruising associated with dental procedures, and accelerating recovery from dental procedures and other oral procedures or trauma.

The present invention is directed to a compound of Formula (I): where, A, R, R1, R2, Y, l, and n are as defined herein. The present invention is also directed to the use of these compounds for the treatment of pain, respiratory 5 depression, or mood or substance use disorders.

A method for treating pain or discomfort in a patient is disclosed. The method comprises stimulating a cranial nerve with an electrical signal. The pain or discomfort may be a withdrawal symptom. The cranial nerve may be in an auricular area of the patient. The cranial nerve may be cranial nerve V, cranial nerve VII, cranial nerve IX, cranial nerve X, or branches of greater and lesser occipital nerves thereof and their associated neurovascular bundles. The withdrawal symptom may result from cessation of an opioid. The method may further comprise administering a secondary drug treats one or more of the withdrawal symptoms and addiction. The secondary drug may be administered about one day to about one week after initiating the stimulating step.

Disclosed herein are pharmaceutical compositions having a mixture of at least one active agent, an ion exchange resin, a binder, and a matrix material such that the composition, when administered to a patient in need thereof, provides the patient with a therapeutic effect for at least about 8 hours and related methods. Also disclosed herein are pharmaceutical compositions having a mixture of a drug susceptible to abuse, a non-opioid analgesic and an ion exchange resin, the composition further including at least one gelling agent and related methods.

The invention provides a pharmaceutical ticagrelor composition for use in the treatment or prevention of coagulation in a patient in need thereof who is co- administered an opioid active ingredient, in combination with a pharmaceutically acceptable carrier, characterized in that the pharmaceutical ticagrelor composition is administered intravenously following the administration of the opioid active ingredient thereby avoiding delayed or reduced ticagrelor uptake provided by the opioid active ingredient; wherein the pharmaceutical ticagrelor composition comprises an inclusion complex of ticagrelor and a cyclodextrin. The invention also provides pharmaceutical ticagrelor composition in lyophilized form and liquid ticagrelor compositions for lyophilization. The invention provides kits comprising a ticagrelor composition in lyophilized form in combination with a suitable diluent. The invention provides methods of manufacturing the pharmaceutically ticagrelor composition in lyophilized form. The reconstituted lyophilized ticagrelor compositions are particularly suitable for use in overcoming delays or reduction in ticagrelor absorption by concomitant opioid drug use.

To provide a pharmaceutical product useful for the treatment or prevention of opioid δ receptor-related diseases. [Solution] The present invention relates to a pharmaceutical composition comprising a morphinan derivative that exerts opioid δ receptor agonist activity. By administering the pharmaceutical composition provided by the present invention, opioid δ receptor-related diseases (e.g., headaches) may be treated or prevented.

(Main claim) Disposal container for the irreversible deactivation of anesthetic drug residues, comprising a multi-layered binding system arranged from top to bottom and including: 1. an upper layer of adsorbent and / or ion exchange resin, 2. a middle layer of activated carbon or another adsorption matrix, 3. a lower layer of a polymer gel for solidifying residual liquids, the layers are designed in such a way that propofol, opioids and ketamine are bound and solidified sequentially, and recovery of the active ingredients is impossible.

The present invention discloses an opioid derivative, an intermediate thereof and a preparation method thereof. The present invention provides a preparation method of a compound represented by formula A6. The preparation method comprises the following step S7: under the action of a palladium catalyst, a phosphine ligand represented by formula L1 and a base, carrying out the dearomatization cyclization reaction shown below on the compound represented by formula A5 in an organic solvent to obtain the compound represented by formula A6. By using the synthesis route and intermediate of the present invention, it is possible to prepare opioid compounds starting from cheap and easily available vanillin and isovanillin, providing the possibility for its large-scale production.

Cannabinoids and terpenoids, which are non-psychoactive elements found in stressed plants, are being studied as possible supplemental treatments for symptoms of drug withdrawal related to remodeling. The therapeutic properties, in addition to reducing cue-induced drug cravings, are very relevant to opioid, cocaine, or cannabis withdrawal syndromes and should be included in standard detoxification programs to mitigate the symptoms of drug withdrawal. Since there is no way to stop this addiction without suffering from serious adverse effects or developing a self-addiction to pharmacological therapies, opioids, cocaine, and cannabis are extremely addictive substances. Using low-dose mixtures of terpenes, terpenoids, and cannabinoids, this innovation seeks to provide a revolutionary anti-addictive analgesic regimen that will safely and effectively cure individuals who are addicted to opioids, cannabinoids, cocaine, or self-addictive substances. Blocking the effects of addiction by inhibiting physiological metabolic processes, these compounds have safe and effective pharmacological, neurobiological, and psychological mechanisms for curing addiction.

To provide a system for evaluating the binding response of β-arrestin 2 to opioid μ receptor.SOLUTION: Provided is a transformed animal cultured cell into which a gene encoding a fusion protein containing an opioid μ receptor, a gene encoding a fusion protein containing β-arrestin 2, and a gene encoding G protein-coupled receptor kinase 2 are introduced, and in which a fused protein which is either one of the fusion protein containing the opioid μ receptor or the fusion protein containing the β-arrestin 2 contains luciferase consisting of an amino acid sequence set forth in SEQ ID NO: 1, and the other fusion protein contains a protein tag consisting of an amino acid sequence set forth in SEQ ID NO: 3. Also provided are a method for evaluating a β-arrestin 2 activation level mediated by a test substance via the opioid μ receptor, and a method for screening for a biased opioid μ receptor agonist, by using the same.SELECTED DRAWING: None

The application provides a novel peptide multi-target ligand molecule based on a kappa-opioid and sigma 1 receptor system, the ligand is a multi-target ligand based on a kappa-opioid / sigma 1 receptor system obtained by using a kappa-opioid receptor agonist CR845 and a sigma 1 receptor antagonist S1RA as chemical template molecules and sharing a pharmacophore. Animal in-vivo pharmacological identification shows that the multi-target peptide ligand of the application can produce analgesic effect in various preclinical pain models, the kappa-like side effects of sedation and depression are reduced compared with the template molecule CR845, and there is no side effect of analgesic tolerance. Therefore, the multi-target ligand based on the kappa-opioid and / or sigma 1 receptor system provided by the application has the value of developing a new analgesic drug with low side effects.